

From: [Woodcock, Janet](#)
To: [Kessler, David \(HHS/IOS\)](#); [Collins, Francis \(NIH/OD\) \[E\]](#); [Fauci, Anthony \(NIH/NIAID\) \[E\]](#); [Bugin, Kevin \(FDA/CDER\)](#); [Teyhen, Deydre \(HHS/IOS\)](#); [Adam, Stacey \(FNIH\) \[T\]](#)
Subject: FW: [EXTERNAL] URGENT: The BIRD meeting proceedings and recommendation on covid-19 prevention and treatment
Date: Friday, February 26, 2021 1:20:25 PM
Attachments: [Draft BIRD Proceedings 25-02-2021 v 1.4.pdf](#)

(b) (5). jw

From: Tess Lawrie <tess@e-bmc.co.uk>
Sent: Friday, February 26, 2021 10:59 AM
To: Abernethy, Amy <Amy.Abernethy@fda.hhs.gov>; Anderson, Erika <Erika.Anderson@fda.hhs.gov>; Yiannas, Frank <Frank.Yiannas@fda.hhs.gov>; james.sigg@fda.hhs.gov; Tyler, James <James.Tyler@fda.hhs.gov>; Tierney, Julia <Julia.Tierney@fda.hhs.gov>; Hinton, Denise <Denise.Hinton@fda.hhs.gov>; Raza, Mark <Mark.Raza@fda.hhs.gov>; Abdoo, Mark <Mark.Abdoo@fda.hhs.gov>; Araojo, Richardae <Richardae.Araojo@fda.hhs.gov>; McMeekin, Judith <Judith.McMeekin@fda.hhs.gov>; Rebello, Heidi <Heidi.Rebello@fda.hhs.gov>; Roth, Lauren <Lauren.Roth@fda.hhs.gov>; Tantillo, Andrew <Andrew.Tantillo@fda.hhs.gov>; Vasisht, Kaveeta <Kaveeta.Vasisht@fda.hhs.gov>; Felberbaum, Michael <Michael.Felberbaum@fda.hhs.gov>; Mair, Michael <Michael.Mair@fda.hhs.gov>; Mettler, Erik <Erik.Mettler@fda.hhs.gov>; Miller, Elizabeth <Elizabeth.Miller@fda.hhs.gov>; Rogers, Michael <Michael.Rogers@fda.hhs.gov>; Cavazzoni, Patrizia <Patrizia.Cavazzoni@fda.hhs.gov>; Marks, Peter <Peter.Marks@fda.hhs.gov>; Mayne, Susan <Susan.Mayne@fda.hhs.gov>; Pazdur, Richard <Richard.Pazdur@fda.hhs.gov>; Jeffrey.shuren@fda.hhs.gov; Slikker, William <William.Slikker@fda.hhs.gov>; Solomon, Steven M <Steven.Solomon@fda.hhs.gov>; Mitch.zeller@fda.hhs.gov; Stein, Peter <Peter.Stein@fda.hhs.gov>; Woodcock, Janet <Janet.Woodcock@fda.hhs.gov>; Sally.chloe@fda.hhs.gov
Cc: claire Mock-Muñoz de Luna <claire@e-bmc.co.uk>; Ketan Gajjar <ketan.gajjar@nhs.net>; Andy Bryant <andy.bryant@newcastle.ac.uk>; Tony Tham (b) (6); Scott Mitchell <scott.mitchell@gov.gg>; Tina Peers <tina@drtinapeers.com>
Subject: [EXTERNAL] URGENT: The BIRD meeting proceedings and recommendation on covid-19 prevention and treatment

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Dr. Stein and FDA Colleagues,

We are writing to share with you the evidence to decision framework of the British Ivermectin Recommendation Development (BIRD) Meeting that was held on Saturday 20th February 2021 via Zoom from Bath, United Kingdom. The expert panel of health and allied professionals and other stakeholders included representatives from 16 countries, namely Argentina, Australia, Belgium, Botswana, Canada, France, Hungary, India, Ireland, Japan, Peru, Nigeria, South Africa, The Philippines, United States, United Kingdom. The ethos of the BIRD meeting was that of scientific rigour and transparency in the spirit of international collaboration towards a common goal – that of saving lives.

The recommendation was developed according *The WHO Handbook of Guideline Development (2014)*. BIRD panel conclusions are that ivermectin should be approved immediately for prevention and treatment of covid-19.

The BIRD recommendation on covid-19 prevention and treatment

The British Ivermectin Recommendation Development Panel recommends ivermectin for the prevention and treatment of covid-19 to reduce morbidity and mortality associated with covid-19 infection and to prevent covid-19 infection among those at higher risk.

The BIRD Steering Group has taken heed of the WHO statement on 'Developing global norms for sharing data and results during public health emergencies' that states that 'public disclosure of information of relevance to public health emergencies should not be delayed', and also notes the 'very great risks' that can occur from 'withholding data and results arising from analyses'. We are, therefore, sharing this evidence-to-decision framework within just a few days of the BIRD meeting to avoid delay.

Further, due to the urgency related to the communication and dissemination of this recommendation that is aimed at saving thousands of lives daily, please forgive the limitations of the draft proceedings document attached. Information on the process and methods can be found among the annexes. An Executive Summary is being finalised and will be available on Monday.

We look forward to hearing from you soon and would be happy meet with you via teleconference if you think this will be helpful.

Please do not hesitate to contact us with any questions.

Kind regards,

Dr. Tess Lawrie, on behalf of the BIRD Steering Group and Recommendation Development Panel
Evidence-based Medicine Consultancy Ltd
e-bmc.co.uk

(b) (4)







(b) (4)


BIRD Working draft version 1.3


(b) (4)






























Obtained via FOIA by Judicial Watch, Inc.























Obtained via FOIA by Judicial Watch, Inc.

Obtained via FOIA by Judicial Watch, Inc.

Obtained via FOIA by Judicial Watch, Inc.





Obtained via FOIA by Judicial Watch, Inc.



Obtained via FOIA by Judicial Watch, Inc.

Obtained via FOIA by Judicial Watch, Inc.

Obtained via FOIA by Judicial Watch, Inc.

Obtained via FOIA by Judicial Watch, Inc.